UofL Researchers Link Urolithin A to Gut Barrier Repair in IBD via 1 Cell Pathway
Updated
Updated · SciTechDaily · Aug 20
UofL Researchers Link Urolithin A to Gut Barrier Repair in IBD via 1 Cell Pathway
1 articles · Updated · SciTechDaily · Aug 20
Summary
Nature Communications published University of Louisville findings that Urolithin A triggers a gut-protective repair program in intestinal epithelial cells, offering a potential route to more targeted IBD treatments.
Urolithin A activated the Aryl hydrocarbon receptor and then the NLRP6 inflammasome, which in this setting boosted mucus production, antimicrobial defense and barrier strength rather than driving damaging inflammation.
Human IBD tissue, organoids and cell studies showed the same pathway, strengthening evidence that the mechanism could matter beyond animal or lab models.
The compound is made when gut microbes break down ellagitannins and ellagic acid from foods such as pomegranates, walnuts and berries, meaning patients may produce different amounts depending on their microbiome.
That variability suggests future therapies may focus less on broad immune suppression and more on restoring intestinal balance by improving how the body makes or uses Urolithin A.
If urolithin A triggers inflammasomes to heal rather than harm, could this postbiotic completely redefine how we treat autoimmune barrier diseases?
Since not all microbiomes produce urolithin A, will future IBD treatments rely on personalized postbiotic supplements rather than simple dietary changes?